血管紧张素II治疗血管舒张性休克
本研究为随机双盲安慰剂对照试验,纳入正在接受去甲肾上腺素>0.2 μg/kg/min或等效剂量其他升压药的血管舒张性休克患者,随机接受血管紧张素II或安慰剂输注。主要终点为输注开始后3小时平均动脉压应答(较基线升高≥10 mmHg或升至≥75 mmHg,且背景升压药剂量未增加),血管紧张素II组应答率69.9%(114/163)显著高于安慰剂组23.4%(37/158),OR 7.95(95%CI 4.76–13.3,P<0.001)。48小时心血管SOFA评分改善血管紧张素II组优于安慰剂组(-1.75 vs -1.28,P=0.01)。28天死亡率血管紧张素II组46%(75/163) vs 安慰剂组54%(85/158),HR 0.78(95%CI 0.57–1.07,P=0.12),未达统计学显著。严重不良事件发生率两组分别为60.7%和67.1%。
要点
- 主要终点3小时升压应答率:血管紧张素II组69.9%(114/163) vs 安慰剂组23.4%(37/158),OR 7.95(95%CI 4.76–13.3,P<0.001)。
- 48小时心血管SOFA评分平均改善:血管紧张素II组-1.75 vs 安慰剂组-1.28(P=0.01)。
- 28天死亡率:血管紧张素II组46%(75/163) vs 安慰剂组54%(85/158),HR 0.78(95%CI 0.57–1.07,P=0.12),未达统计学显著。
- 严重不良事件发生率:血管紧张素II组60.7% vs 安慰剂组67.1%。
- 纳入标准:正在接受去甲肾上腺素>0.2 μg/kg/min或等效剂量其他升压药的血管舒张性休克患者。
适用人群与场景
- 正在接受去甲肾上腺素>0.2 μg/kg/min或等效剂量其他升压药治疗的血管舒张性休克患者。
诊断标准与关键阈值
- 升压应答定义:输注开始后3小时平均动脉压较基线升高≥10 mmHg或升至≥75 mmHg,且背景升压药剂量未增加。
处置流程与药物剂量
- 随机接受血管紧张素II或安慰剂输注,具体剂量方案原文未报告。
研究设计与关键结果
- 随机双盲安慰剂对照试验,共344例患者被随机分配,321例接受研究干预并纳入分析(血管紧张素II组163例,安慰剂组158例)。
- 主要终点3小时升压应答率:血管紧张素II组69.9%(114/163) vs 安慰剂组23.4%(37/158),OR 7.95(95%CI 4.76–13.3,P<0.001)。
- 48小时心血管SOFA评分平均改善:血管紧张素II组-1.75 vs 安慰剂组-1.28(P=0.01)。
- 严重不良事件:血管紧张素II组60.7% vs 安慰剂组67.1%。
- 28天死亡:血管紧张素II组46%(75/163) vs 安慰剂组54%(85/158),HR 0.78(95%CI 0.57–1.07,P=0.12)。
证据类型、等级与局限
- 证据类型:随机双盲安慰剂对照试验(ATHOS-3,ClinicalTrials.gov NCT02338843)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于高剂量常规升压药无反应的血管舒张性休克患者,血管紧张素II可有效升高血压(作者结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Vasodilatory shock that does not respond to high-dose vasopressors is associated with high mortality. We investigated the effectiveness of angiotensin II for the treatment of patients with this condition.
METHODS: We randomly assigned patients with vasodilatory shock who were receiving more than 0.2 μg of norepinephrine per kilogram of body weight per minute or the equivalent dose of another vasopressor to receive infusions of either angiotensin II or placebo. The primary end point was a response with respect to mean arterial pressure at hour 3 after the start of infusion, with response defined as an increase from baseline of at least 10 mm Hg or an increase to at least 75 mm Hg, without an increase in the dose of background vasopressors.
RESULTS: A total of 344 patients were assigned to one of the two regimens; 321 received a study intervention (163 received angiotensin II, and 158 received placebo) and were included in the analysis. The primary end point was reached by more patients in the angiotensin II group (114 of 163 patients, 69.9%) than in the placebo group (37 of 158 patients, 23.4%) (odds ratio, 7.95; 95% confidence interval [CI], 4.76 to 13.3; P<0.001). At 48 hours, the mean improvement in the cardiovascular Sequential Organ Failure Assessment (SOFA) score (scores range from 0 to 4, with higher scores indicating more severe dysfunction) was greater in the angiotensin II group than in the placebo group (-1.75 vs. -1.28, P=0.01). Serious adverse events were reported in 60.7% of the patients in the angiotensin II group and in 67.1% in the placebo group. Death by day 28 occurred in 75 of 163 patients (46%) in the angiotensin II group and in 85 of 158 patients (54%) in the placebo group (hazard ratio, 0.78; 95% CI, 0.57 to 1.07; P=0.12).
CONCLUSIONS: Angiotensin II effectively increased blood pressure in patients with vasodilatory shock that did not respond to high doses of conventional vasopressors. (Funded by La Jolla Pharmaceutical Company; ATHOS-3 ClinicalTrials.gov number, NCT02338843 .).
参考来源
- Khanna A, English SW, Wang XS, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017. PMID: 28528561. doi:10.1056/NEJMoa1704154
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。